Keywords

Biliary Tract Pancreatic Cholangiocarcinoma Brightline2 MDM2-p53

JUNE 26, 2023
STEVE HOLMES
Summary Edition for Patient & caregivers
Sources: Boehringer Ingelheim 

Introduction

Boehringer Ingelheim has developed an investigational drug, BI 907828, which targets MDM2-p53 antagonist. This drug is being tested in the Brightline-2 clinical trial (Clinicaltrials.gov identifier: NCT05512377) for people with advanced cancer in the biliary tract or pancreas, featuring MDM2 amplification and TP53 wild-type status, confirmed through molecular profiling. This article provides an overview of the trial and its potential benefits.

What is MDM2?: MDM2 stands for “mouse double minute 2 homolog.” It is a protein that interacts with the tumor suppressor protein p53, which is responsible for preventing tumor growth. MDM2 can bind to p53 and prevent it from carrying out its normal function, allowing tumors to grow unchecked. Investigational drugs that target MDM2, such as BI 907828, are being studied as potential cancer treatments.

What is 2 homolog?: 2 homolog” in MDM2 stands for a protein that is similar to a protein found in mice. Specifically, it is the human equivalent of the mouse double minute 2 protein.

Not Mentioned: The article does not mention any specific results achieved by the Brightline-2 clinical trial of BI 907828. The article focuses on the need for new treatment options for rare and aggressive cancers, and the potential of MDM2-p53 antagonist drugs like BI 907828. The article also highlights the collaborative approach being taken by Boehringer Ingelheim and Foundation Medicine for companion diagnostic development.

Understanding Cholangiocarcinoma

Cholangiocarcinoma is a rare and aggressive cancer that affects the bile ducts in the liver. It is difficult to diagnose and treat, with a poor prognosis for most patients. For patients and caregivers, it is important to understand the nature of cholangiocarcinoma and its treatment options.

The Brightline-2 Clinical Trial

Boehringer Ingelheim’s Brightline-2 clinical trial is investigating BI 907828 as monotherapy for the treatment of locally advanced or metastatic MDM2-amplified TP53 wild-type biliary tract adenocarcinoma, pancreatic ductal adenocarcinoma, or other selected solid tumors that are not suitable for targeted treatment and/or standard of care therapy. The trial is in phase IIa/IIb and is currently recruiting participants.

Potential Benefits of BI 907828

BI 907828 targets MDM2-p53 antagonist, which is a protein that interacts with the tumor suppressor protein p53 responsible for preventing tumor growth. MDM2 can bind to p53 and prevent it from carrying out its normal function, allowing tumors to grow unchecked. Investigational drugs like BI 907828 that target MDM2 are being studied as potential cancer treatments. The trial is currently ongoing, and it is too early to provide definitive results. However, the potential benefits of BI 907828 for cholangiocarcinoma patients and caregivers are promising.

Collaborative Approach

Boehringer Ingelheim is partnering with Foundation Medicine, a leader in molecular profiling, for companion diagnostic development. The partnership aims to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for BI 907828 in the United States, European Union, and Japan.

Conclusion

Boehringer Ingelheim’s goal is to transform the lives of people with cancer by delivering meaningful advances, with the ultimate goal of curing a range of cancers. The Brightline-2 clinical trial is currently ongoing, and it is too early to provide definitive results. However, the potential benefits of BI 907828 for cholangiocarcinoma patients and caregivers are promising. For patients and caregivers, it is important to stay informed about the latest developments in cancer research and to discuss treatment options with their healthcare providers.

Key Takeaways

• BI 907828 is being tested in the Brightline-2 clinical trial for people with advanced cancer in the biliary tract or pancreas, featuring MDM2 amplification and TP53 wild-type status, confirmed through molecular profiling.
• Boehringer Ingelheim is partnering with Foundation Medicine for companion diagnostic development.
• Investigational drugs like BI 907828 that target MDM2 are being studied as potential cancer treatments.
• For patients and caregivers, it is important to stay informed about the latest developments in cancer research and to discuss treatment options with their healthcare providers.